cas 95645-00-4|| where to buy 3-methoxy-2,6-dimethylaniline

Produktname:3-methoxy-2,6-dimethylaniline

IUPAC Name:3-methoxy-2,6-dimethylaniline

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM1032576-5g	in stock	œǺƩ
CM1032576-25g	in stock	œǺƩ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 95645-00-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:95645-00-4; Molekulare Formel:C9H13NO; Schmelzpunkt:-; SMILES-Code:COC1=CC=C(C)C(N)=C1C; Dichte:

: Katalognummer:CM1032576; Molekulargewicht:151.21; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Lunresertib Camonsertib; Repare Therapeutics announces Fast Track Designation granted by the FDA for Lunresertib in combination with Camonsertib for the treatment of platinum-resistant ovarian cancer. Membrane-associated Tyrosine- and Threonine-specific cdc2-inhibitory kinase MYT1 (PKMYT1) is a regulator of CDK1 phosphorylation, and PKMYT1 is identified as synthetic lethal with cyclin E1 (CCNE1) amplification.
Lunresertib (RP-6306) is a first-in-class PKMYT1 inhibitor to enter clinical trial. Lunresertib is studied alone and in combination with Camonsertib in patients with advanced solid tumors. Camonsertib (RP-3500) is a potent and selective ATR inhibitor, that helps Lunresertib activate CDK1 and promotes premature mitosis. The combination is previously granted Fast Track Designation for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer.